亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

医学 安慰剂 人口 病毒载量 临床终点 随机对照试验 内科学 免疫学 人类免疫缺陷病毒(HIV) 环境卫生 病理 替代医学
作者
Andrea Alemany,Pere Millat-Martínez,Marc Corbacho-Monné,Pierre Malchair,Dan Ouchi,Anna Ruiz‐Comellas,Anna Ramírez‐Morros,Joana Rodríguez Codina,Rosa Amado Simon,Sebastián Videla,Gèlia Costes,Mar Capdevila-Jáuregui,Pamela Torrano-Soler,Alba San José,Glòria Bonet Papell,Jordi Puig,Aurema Otero,José Carlos Ruibal Suárez,Alvaro Zarauza Pellejero,Ferrán Llopis Roca
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:10 (3): 278-288 被引量:79
标识
DOI:10.1016/s2213-2600(21)00545-2
摘要

Convalescent plasma has been proposed as an early treatment to interrupt the progression of early COVID-19 to severe disease, but there is little definitive evidence. We aimed to assess whether early treatment with convalescent plasma reduces the risk of hospitalisation and reduces SARS-CoV-2 viral load among outpatients with COVID-19.We did a multicentre, double-blind, randomised, placebo-controlled trial in four health-care centres in Catalonia, Spain. Adult outpatients aged 50 years or older with the onset of mild COVID-19 symptoms 7 days or less before randomisation were eligible for enrolment. Participants were randomly assigned (1:1) to receive one intravenous infusion of either 250-300 mL of ABO-compatible high anti-SARS-CoV-2 IgG titres (EUROIMMUN ratio ≥6) methylene blue-treated convalescent plasma (experimental group) or 250 mL of sterile 0·9% saline solution (control). Randomisation was done with the use of a central web-based system with concealment of the trial group assignment and no stratification. To preserve masking, we used opaque tubular bags that covered the investigational product and the infusion catheter. The coprimary endpoints were the incidence of hospitalisation within 28 days from baseline and the mean change in viral load (in log10 copies per mL) in nasopharyngeal swabs from baseline to day 7. The trial was stopped early following a data safety monitoring board recommendation because more than 85% of the target population had received a COVID-19 vaccine. Primary efficacy analyses were done in the intention-to-treat population, safety was assessed in all patients who received the investigational product. This study is registered with ClinicalTrials.gov, NCT04621123.Between Nov 10, 2020, and July 28, 2021, we assessed 909 patients with confirmed COVID-19 for inclusion in the trial, 376 of whom were eligible and were randomly assigned to treatment (convalescent plasma n=188 [serum antibody-negative n=160]; placebo n=188 [serum antibody-negative n=166]). Median age was 56 years (IQR 52-62) and the mean symptom duration was 4·4 days (SD 1·4) before random assignment. In the intention-to-treat population, hospitalisation within 28 days from baseline occurred in 22 (12%) participants who received convalescent plasma versus 21 (11%) who received placebo (relative risk 1·05 [95% CI 0·78 to 1·41]). The mean change in viral load from baseline to day 7 was -2·41 log10 copies per mL (SD 1·32) with convalescent plasma and -2·32 log10 copies per mL (1·43) with placebo (crude difference -0·10 log10 copies per mL [95% CI -0·35 to 0·15]). One participant with mild COVID-19 developed a thromboembolic event 7 days after convalescent plasma infusion, which was reported as a serious adverse event possibly related to COVID-19 or to the experimental intervention.Methylene blue-treated convalescent plasma did not prevent progression from mild to severe illness and did not reduce viral load in outpatients with COVID-19. Therefore, formal recommendations to support the use of convalescent plasma in outpatients with COVID-19 cannot be concluded.Grifols, Crowdfunding campaign YoMeCorono.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
雪白书蝶发布了新的文献求助10
3秒前
荷兰香猪发布了新的文献求助10
7秒前
12秒前
23秒前
雪白书蝶完成签到,获得积分10
23秒前
Moto_Fang完成签到 ,获得积分10
24秒前
31秒前
35秒前
KaK完成签到,获得积分10
35秒前
Lemenchichi完成签到,获得积分10
51秒前
今后的应助被荷兰香猪采纳,获得10
1分钟前
1分钟前
木槿花有枝芽完成签到 ,获得积分10
1分钟前
荷兰香猪发布了新的文献求助10
1分钟前
1分钟前
1分钟前
1分钟前
zilicai的应助被科研通管家采纳,获得60
1分钟前
852的应助被科研通管家采纳,获得10
1分钟前
1分钟前
Kiuhirng发布了新的文献求助100
1分钟前
科研通AI6.3的应助被amiee采纳,获得10
1分钟前
2分钟前
amiee发布了新的文献求助10
2分钟前
2分钟前
自然的妙梦完成签到,获得积分10
3分钟前
yc关闭了yc的文献求助
3分钟前
3分钟前
vitamin完成签到 ,获得积分0
3分钟前
Orange的应助被荷兰香猪采纳,获得10
3分钟前
3分钟前
荷兰香猪发布了新的文献求助10
3分钟前
漂亮的半兰完成签到,获得积分10
4分钟前
4分钟前
Heart_of_Stone完成签到 ,获得积分10
5分钟前
5分钟前
友好大树发布了新的文献求助10
5分钟前
gd完成签到 ,获得积分10
5分钟前
科研通AI65的应助被amiee采纳,获得10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577257
关于积分的说明 21852297
捐赠科研通 7788567
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880